Study purpose: The purpose of this study is to track changes that occur to the immune system of women with MS, NMOSD and those that do not have these conditions during pregnancy and to determine how these changes might protect against long-term disease progression.

Who is eligible?

• Are >18 years old
• Diagnosed with MS or NMOSD
• Have never been pregnant and are planning a pregnancy in the next two years
• Willing to provide a blood sample before pregnancy, in the first trimester, third trimester and 1 month post partum
• Willing to complete surveys (can be done at home) in the first trimester, third trimester and 1 month post partum
• Other criteria required to be reviewed

Recruitment: Open!

Study contact: Vicky Maltby

Study purpose: To determine if magnetic brain stimulation can help repair myelin in MS.

Who is eligible?

• Aged 18 – 65 years
• Diagnosed with MS
• Willing to travel to site every weekday for 4 consecutive weeks
• Stable disease for 24 weeks
• Not previously received any form of rTMS
• Able to tolerate MRI
• No history of seizures, epilepsy, stroke, brain surgery, bipolar, mania, claustrophobia, or serious head trauma*, substance abuse*, migraines*
• Not currently taking tricyclic antidepressants, neuroleptics, antipsychotics or antiseizure medication for the treatment of any indications listed above
• Not pregnant
• Not currently involved in another interventional clinical trial
• Other criteria required to be reviewed

Recruitment: Closed

Study contact: Nicole Lingard

More information: here

Study purpose: to determine whether dietary supplements (like vitamins and antioxidants) can help relieve fatigue in MS.

Who is eligible?

• Aged 18 – 65 years
• Diagnosis of relapsing MS
• Stable MS treatment for (>2 months) or untreated
• Experiencing fatigue
• Able to tolerate MRI
• Stable MS for 90 days
• Not pregnant or breast feeding
• No thyroid disorder, or recent gastrointestinal ulcers or renal stones
• On stable antidepressants for 4 weeks
• Able to take large tablets for 4 consecutive months
• Other criteria required to be reviewed

Recruitment: Closed

Study contact: Kira Groen

More Information: here

Study purpose: MOGAD is a rare condition that affects the central nervous system. The aim of this study is to test how effective and safe satralizumab is for treating adults and teenagers with MOGAD. The METEOROID study will look to see if satralizumab is safe and whether it works as treatment for MOGAD – for both preventing attacks and improving symptoms.

Who is eligible?

• Aged >12 years
• Diagnosis of MOG antibody disease
• Documented history of ≥2 MOGAD attacks
• Stable disease for 12 weeks before first dose
• No present or recurrent bacterial, viral, fungal, or other infection (excluding fungal infection of nail beds or dental caries)
• Able to tolerate MRI
• No history of cancer or other significant medical conditions
• Not pregnant or breast feeding
• Other criteria required to be reviewed

Recruitment: Open for enrollment!

Study contact: Nicole Lingard

More information: here

Study purpose: Primary progressive multiple sclerosis (PPMS) affects approximately 10-15% of people with MS. At present, ocrelizumab is the only approved treatment for the condition. The aim of the FENtrepid study is to see if the new trial medication could offer a safe and effective treatment option for PPMS.

Who is eligible?

• Aged 18 – 65 years
• Diagnosis of primary progressive MS
• Disability progression in the last 12 months
• Stable medications for at least 4 weeks prior to starting the study
• Able to tolerate MRI
• Stable MS for 30 days
• Not pregnant or breast feeding
• Able to walk (with bilateral assistance is required) for 8 metres
• No infection (viral, fungal, bacterial) within 8 weeks
• No history of cancer or other significant medical conditions
• Other criteria required to be reviewed

Recruitment: Closed

Study contact: Bente Saugbjerg / Nicole Lingard

More information: here